Want to see GDTC full AI Analyst Report?
Top Page
CytoMed Therapeutics Limited
(NASDAQ:GDTC)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.85
▼(-10.74% Downside)
Action:Reiterated
Date:10/17/26
The score is primarily held down by weak financial performance—large operating/net losses and persistent negative free cash flow—despite strong recent revenue growth and modest leverage. Technicals add pressure with price trading below key moving averages and a negative MACD. Valuation is difficult to support with a negative P/E and no indicated dividend yield.
Positive Factors
Revenue Growth
The sharp increase in TTM revenue indicates meaningful commercial expansion and growing activity in the business. If the company can retain this trajectory while controlling costs, a larger revenue base could eventually support operating leverage and improve the economics of its development programs.
Negative Factors
Persistent Cash Burn
Persistent negative operating and free cash flow means the business is consuming cash rather than funding itself internally. Unless burn moderates, continued reliance on external capital may constrain strategic flexibility, increase financing requirements, and make pipeline investment harder to sustain.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The sharp increase in TTM revenue indicates meaningful commercial expansion and growing activity in the business. If the company can retain this trajectory while controlling costs, a larger revenue base could eventually support operating leverage and improve the economics of its development programs.
Read all positive factors
CytoMed Therapeutics Limited (GDTC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$10.53M
Dividend YieldN/A
Average Volume (3M)17.68K
Price to Earnings (P/E)―
Beta (1Y)<0.01
Revenue Growth49.09%
EPS Growth3.91%
CountryUS
Employees42
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,832,835
10 Day Avg. Volume14,725
30 Day Avg. Volume17,679
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)3.07
Price to Sales (P/S)61.86
P/FCF Ratio-4.56
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue16.37
Enterprise Value/Gross Profit-2.83
Enterprise Value/Ebitda-2.44
Forecast
1Y Price Target
$4.16Price Target Upside337.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CytoMed Therapeutics Limited Business Overview & Revenue Model
Company Description
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignan...
How the Company Makes Money
null...
CytoMed Therapeutics Limited Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
58
Neutral
Cash Flow
27
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 720.31K | 324.39K | 69.50K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -4.16M | 256.39K | 52.38K | -4.36M | 0.00 | 110.29K |
| EBITDA | -4.84M | -3.57M | -2.17M | -3.70M | -2.61M | -1.56M |
| Net Income | -5.26M | -3.98M | -2.52M | -4.13M | -3.13M | -2.07M |
Balance Sheet | ||||||
| Total Assets | 7.01M | 7.98M | 10.07M | 12.40M | 5.25M | 6.10M |
| Cash, Cash Equivalents and Short-Term Investments | 1.46M | 2.10M | 4.97M | 9.02M | 1.59M | 2.53M |
| Total Debt | 453.76K | 482.56K | 463.15K | 449.25K | 4.24M | 3.27M |
| Total Liabilities | 1.61M | 1.13M | 1.02M | 1.13M | 4.66M | 3.50M |
| Stockholders Equity | 4.97M | 6.54M | 8.96M | 11.28M | 589.71K | 2.60M |
Cash Flow | ||||||
| Free Cash Flow | -6.30M | -4.40M | -4.11M | -3.60M | -1.88M | -2.30M |
| Operating Cash Flow | -5.58M | -3.70M | -2.71M | -3.54M | -1.40M | -1.72M |
| Investing Cash Flow | 1.70M | 929.28K | 1.13M | -2.73M | -475.51K | -825.59K |
| Financing Cash Flow | 1.53M | 208.65K | -64.88K | 10.92M | 968.35K | 4.18M |
CytoMed Therapeutics Limited Technical Analysis
Neutral
0.95
Price Trends
0.90
Positive
0.95
Negative
0.98
Negative
Market Momentum
<0.01
Negative
53.51
Neutral
87.55
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GDTC, the sentiment is Neutral. The current price of 0.95 is above the 20-day moving average (MA) of 0.90, above the 50-day MA of 0.90, and below the 200-day MA of 0.98, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 53.51 is Neutral, neither overbought nor oversold. The STOCH value of 87.55 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GDTC.
CytoMed Therapeutics Limited Risk Analysis
CytoMed Therapeutics Limited disclosed 106 risk factors in its most recent earnings report. CytoMed Therapeutics Limited reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
CytoMed Therapeutics Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $15.02M | >-0.01 | -147.45% | ― | ― | ― | |
46 Neutral | $10.78M | -0.30 | -218.59% | ― | ― | 38.14% | |
44 Neutral | $7.58M | -0.28 | -209.67% | ― | ― | 79.26% | |
43 Neutral | $10.53M | -2.60 | -91.37% | ― | 49.09% | 3.91% |
* Healthcare Sector Average
GDTC
CytoMed Therapeutics Limited
0.89
-1.50
-62.76%
AKTX
Akari Therapeutics
8.58
-22.27
-72.19%
MTVA
MetaVia
1.15
-9.58
-89.28%
PASG
Passage Bio
3.35
-4.31
-56.27%
KAPA
Kairos Pharma, Ltd.
0.53
-7.45
-93.36%
CytoMed Therapeutics Limited Corporate Events
CytoMed Therapeutics Posts Narrower Interim Loss in June 2026 SEC Filing
Sep 30, 2026
CytoMed Therapeutics Limited has filed a Form 6-K with the U.S. Securities and Exchange Commission for the financial period ended June 30, 2026, furnishing unaudited interim condensed consolidated financial statements and management’s discus...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.